Evyatar Evron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evyatar Evron has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Amanda M. Nelson
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, Pennsylvania, USA
1 shared publication Arash Babadjouni
Arizona College of Osteopathic Medicine, Midwestern University, Glendale, Arizona, USA
1 shared publication- Avi Harlev
Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben-Gurion University of the Negev, Beer-Sheva, Israel
1 shared publication - Eyal Sheiner
Department of Obstetrics and Gynecology, Soroka University Medical Center, Ben Gurion University of the Negev, Beer-Sheva, Israel
1 shared publication - George W. Agak
Division of Dermatology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, California, USA
1 shared publication - Jenny Kim
Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
1 shared publication
Latest Publications
- Open Access
- 5 May 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 3126-3137.e8
Immune Activation and Glycolytic Responses to Cutibacterium acnes Cell Wall Polysaccharides
- 5 May 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (12) , 3126-3137.e8
Open AccessImmune Activation and Glycolytic Responses to Cutibacterium acnes Cell Wall Polysaccharides
- 23 August 2020
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 6 (6) , 329-337
Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia
Saw palmetto (SP), a botanical extract with antiandrogenic properties, has gained commercial popularity for its purported benefits on hair regrowth. To summarize published evidence on the efficacy, safety, and tolerability of supplements containing SP in the treatment of alopecia, we conducted a PubMed, Google Scholar, and Cochrane database search using the following terms: (saw palmetto and hair loss), (saw palmetto and androgenetic alopecia), and (saw palmetto and natural supplement and alopecia). Five randomized clinical trials (RCTs) and 2 prospective cohort studies demonstrated positive effects of topical and oral supplements containing SP (100–320 mg) among patients with androgenetic alopecia (AGA) and telogen effluvium. Sixty percent improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized disease progression among 52% were noted with use of various topical and oral SP-containing supplements. SP was well tolerated and not associated with serious adverse events in alopecia patients. Although robust high-quality data are lacking, supplements containing SP may be a treatment option for patients with AGA, telogen effluvium, and self-perceived hair thinning. Further large-scale RCTs focusing on the sole contribution of SP to hair growth outcomes are needed to confirm efficacy and determine long-term adverse events.
- 23 August 2020
- Published by S. Karger AG in Skin Appendage Disorders
- Vol. 6 (6) , 329-337
Natural Hair Supplement: Friend or Foe? Saw Palmetto, a Systematic Review in Alopecia
Saw palmetto (SP), a botanical extract with antiandrogenic properties, has gained commercial popularity for its purported benefits on hair regrowth. To summarize published evidence on the efficacy, safety, and tolerability of supplements containing SP in the treatment of alopecia, we conducted a PubMed, Google Scholar, and Cochrane database search using the following terms: (saw palmetto and hair loss), (saw palmetto and androgenetic alopecia), and (saw palmetto and natural supplement and alopecia). Five randomized clinical trials (RCTs) and 2 prospective cohort studies demonstrated positive effects of topical and oral supplements containing SP (100–320 mg) among patients with androgenetic alopecia (AGA) and telogen effluvium. Sixty percent improvement in overall hair quality, 27% improvement in total haircount, increased hair density in 83.3% of patients, and stabilized disease progression among 52% were noted with use of various topical and oral SP-containing supplements. SP was well tolerated and not associated with serious adverse events in alopecia patients. Although robust high-quality data are lacking, supplements containing SP may be a treatment option for patients with AGA, telogen effluvium, and self-perceived hair thinning. Further large-scale RCTs focusing on the sole contribution of SP to hair growth outcomes are needed to confirm efficacy and determine long-term adverse events.
- 1 May 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (5) , 1209-1214
Vanishing twin syndrome: is it associated with adverse perinatal outcome?
- 1 May 2015
- Published by Elsevier in Fertility and Sterility
- Vol. 103 (5) , 1209-1214
Vanishing twin syndrome: is it associated with adverse perinatal outcome?